Skip to main content
Premium Trial:

Request an Annual Quote

As Expected, Nasdaq to Delist Tripos 'Shell' From Stock Market

NEW YORK (GenomeWeb News) — As expected, the Nasdaq Stock Market said it plans to file a petition with the US Securities and Exchange Commission to delist Tripos, the market said today.
Nasdaq said the delisting will become effective 10 days after the filing. Tripos has not traded on the Nasdaq since July 6, when the market suspended its stock.
Tripos said at the time that the delisting was expected. The company had recently sold its Discovery Research business and had become a public shell, making its stock ineligible for listing on the Nasdaq.
Tripos also said in July it plans to seek to trade on the Nasdaq’s Over-the-Counter Bulletin Board, and that its stock will be available for quotation on the Pink Sheets electronic quotation service.
The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.